Preference weights for cost-outcome analyses of schizophrenia treatments: comparison of four stakeholder groups.
Preference weights for cost-outcome analyses of schizophrenia treatments: comparison of four stakeholder groups.
复制标题
精神分裂症治疗成本结果分析的偏好权重：四个利益相关者群体的比较。
DOI：
10.1093/oxfordjournals.schbul.a007002
复制
发表时间：
2003
影响因子：
6.6
通讯作者：
Shumway,Martha
中科院分区：
文献类型：
--
作者：
Shumway,Martha
这项研究量化了四个利益相关者群体对精神分裂症结果的偏好，检验了结果不同且利益相关者群体有不同偏好的假设，并为成本-结果分析产生了七个结果的偏好权重。50名精神分裂症患者、50名临床医生、41名患者家属和50名普通公众对16种与精神分裂症相关的健康状态进行了评级，得出了7种结果的偏好权重：阳性症状、阴性症状、锥体外系症状、迟发性运动障碍、社会功能、独立生活和职业功能。结果的重要性不同(F=23.4，p<；0.01)。所有利益相关者都认为阳性症状和社会功能比阴性症状和锥体外系症状更重要。利益相关者群体有不同的偏好(F=1.9，P=0.01)。患者认为锥体外系症状比其他组更重要(p<；0.01)；临床医生认为社会功能比患者或家庭成员更重要(p<；0.05)；临床医生和家庭成员认为职业功能比患者和普通公众更重要(p<；0.05)。结果表明，精神分裂症的结果并不同样重要，利益相关者群体对结果的评价也不同，这表明在成本-结果分析和其他治疗比较中纳入利益相关者偏好的重要性。
This study quantified preferences for schizophrenia outcomes in four stakeholder groups, tested the hypotheses that outcomes differ in importance and stakeholder groups have different preferences, and produced preference weights for seven outcomes for cost-outcome analysis. Fifty patients with schizophrenia, 50 clinicians, 41 family members of patients, and 50 members of the general public rated 16 schizophrenia-related health states, yielding preference weights for seven outcomes: positive symptoms, negative symptoms, extrapyramidal symptoms, tardive dyskinesia, social function, independent living, and vocational function. Outcomes differed in importance (F = 23.4,p< 0.01). All stakeholders rated positive symptoms and social functioning as more important than negative and extrapyramidal symptoms. Stakeholder groups had different preferences (F = 1.9,p= 0.01). Patients rated extrapyramidal symptoms as more important than did other groups (p< 0.01); clinicians rated social functioning as more important than did patients or family members (p< 0.05); and clinicians and family members rated vocational functioning as more important than did patients and the general public (p< 0.05). Results show that schizophrenia outcomes are not equally important and that stakeholder groups value outcomes differently, demonstrating the importance of incorporating stakeholder preferences in cost-outcome analyses and other treatment comparisons.